WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
Related articles:
Related suggestion:
Xi inspects Changde in central China's Hunan ProvinceXi Sends Congratulatory Letter to 6th ChinaXi Focus: A Look at How Xi Jinping Leads China's COVIDAsian, African Diplomats in China Mourn Former Chinese Leader Jiang ZeminChina strengthens crackdown on illegal fishingChina to Continue Working with G20 Members on Global Digital Economic Paradigm: XiChinese Armed Forces Mourn Passing of Jiang ZeminNEV makers encouraged to speed up overseas developmentXi Holds Talks with Lao PresidentXi Says China Committed to Building Asia
2.7173s , 6517.7265625 kb
Copyright © 2024 Powered by Why Amylyx is pulling ALS drug Relyvrio from US market after study ,International Investigation news portal